Commentary
Individuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical records of 253 patients with schizophrenia/schizoaffective disorder who received an abdominal echography.
NAFLD was detected in 108 patients (42.7%). Of these, 13 patients showed signs of fibrosis.
Body mass index, the total dose of antipsychotic drugs that carry a risk of metabolic syndrome, and the total dose of antipsychotic drugs that carry a risk of hyperprolactinaemia were significantly associated with NAFLD. Importantly, the risk in younger female patients may be specific to patients with schizophrenia compared with the general population.the authors, this finding should trigger awareness of non-cardiac comorbidities in patients with pulmonary hypertension.
